Tulika Singh

Tulika Singh

Auto-generated profile, based on publicly available information

Tulika Singh

Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, USA

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
ADAntonio G. Dias
Antonio G. Dias
CACaroline Atyeo
Caroline Atyeo
CLCarolin Loos
Carolin Loos
MMMagelda Montoya
Magelda Montoya
VRVicky Roy
Vicky Roy
EHEva Harris
Eva Harris
Preexisting cross-reactive antibodies have been implicated in both protection and pathogenesis during subsequent infections with different dengue virus (DENV) serotypes (DENV1-4). Nonetheless, humoral immune correlates and mechanisms of protection have remained elusive. Using a systems serology approach to evaluate humoral responses, we profiled plasma collected before inapparent or symptomatic secondary DENV3 infection from our pediatric cohort in Nicaragua. Children protected from symptomatic infections had more anti-envelope (E) and anti–nonstructural protein 1 (NS1) total immunoglobulin G (IgG), IgG4, and greater Fc effector functions than those with symptoms. Fc effector functions were also associated with protection from hemorrhagic manifestations in the pre-symptomatic group. Furthermore, in vitro virological assays using these plasma samples revealed that protection mediated by antibody-dependent complement deposition was associated with both lysis of virions and DENV-infected cells. These data suggest that E- and NS1-specific Fc functions may serve as correlates of protection, which can be potentially applied toward the design and evaluation of dengue vaccines.

8 September 2021 in JCI Insight
Verified
Journal Article
Open access
CGCarolina Garrido
Carolina Garrido
JHJillian H. Hurst
Jillian H. Hurst
CLCynthia G. Lorang
Cynthia G. Lorang
JAJhoanna N. Aquino
Jhoanna N. Aquino
JRJavier Rodriguez
Javier Rodriguez
GFGenevieve G. Fouda
Genevieve G. Fouda
As SARS-CoV-2 continues to spread globally, questions have emerged regarding the strength and durability of immune responses in specific populations. In this study, we evaluated humoral immune responses in 69 children and adolescents with asymptomatic or mild symptomatic SARS-CoV-2 infection. We detected robust IgM, IgG, and IgA antibody responses to a broad array of SARS-CoV-2 antigens at the time of acute infection and 2 and 4 months after acute infection in all participants. Notably, these antibody responses were associated with virus-neutralizing activity that was still detectable 4 months after acute infection in 94% of children. Moreover, antibody responses and neutralizing activity in sera from children and adolescents were comparable or superior to those observed in sera from 24 adults with mild symptomatic infection. Taken together, these findings indicate that children and adolescents with mild or asymptomatic SARS-CoV-2 infection generate robust and durable humoral immune responses that can likely contribute to protection from reinfection.

18 December 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
KRKoen K.A. Van Rompay
Koen K.A. Van Rompay
RKRebekah I. Keesler
Rebekah I. Keesler
Amir ArdeshirAmir Ardeshir
Amir Ardeshir
JWJennifer Watanabe
Jennifer Watanabe
JUJodie Usachenko
Jodie Usachenko
BGBarney S. Graham
Barney S. Graham
A Zika virus vaccine administered to macaques before conception reduces maternal viremia and improves fetal outcomes.

17 December 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
GYGlenn Yiu
Glenn Yiu
STSara M. Thomasy
Sara M. Thomasy
MCM. Isabel Casanova
M. Isabel Casanova
ARAlexander Rusakevich
Alexander Rusakevich
RKRebekah I. Keesler
Rebekah I. Keesler
KRKoen K.A. Van Rompay
Koen K.A. Van Rompay
Congenital Zika syndrome (CZS) is associated with microcephaly and various neurological, musculoskeletal, and ocular abnormalities, but the long-term pathogenesis and postnatal progression of ocular defects in infants are not well characterized. Rhesus macaques are superior to rodents as models of CZS because they are natural hosts of the virus and share similar immune and ocular characteristics, including blood–retinal barrier characteristics and the unique presence of a macula. Using a previously described model of CZS, we infected pregnant rhesus macaques with Zika virus (ZIKV) during the late first trimester and characterized postnatal ocular development and evolution of ocular defects in 2 infant macaques over 2 years. We found that one of them exhibited colobomatous chorioretinal atrophic lesions with macular and vascular dragging as well as retinal thinning caused by loss of retinal ganglion neuron and photoreceptor layers. Despite these congenital ocular malformations, axial elongation and retinal development in these infants progressed at normal rates compared with healthy animals. The ZIKV-exposed infants displayed a rapid loss of ZIKV-specific antibodies, suggesting the absence of viral replication after birth, and did not show any behavioral or neurological defects postnatally. Our findings suggest that ZIKV infection during early pregnancy can impact fetal retinal development and cause congenital ocular anomalies but does not appear to affect postnatal ocular growth.

9 March 2017 in Journal of Cancer Policy
Verified
Journal Article
Open access
PDF file
TSTulika Singh
Tulika Singh
PPPaul C. Pearlman
Paul C. Pearlman
BKBrenda Kostelecky
Brenda Kostelecky
The steady increase in cancer incidence and mortality in the Asia-Pacific presents a growing challenge to countries in the region. National cancer control planning provides key strategies for countries to decrease their cancer burden and address risk factors in the context of their populations and health systems. Evidence-guided approaches allow countries to target resources towards highly-needed and effective cancer programs, while partnerships can serve to diversify sources of support, increase coverage and sustain services. Many countries struggle to develop and implement national cancer control plans (NCCPs) due to barriers in coordinating diverse stakeholders, limited funding and absence of evidence to guide program and health infrastructure improvements. The Cancer Control Leadership Forum (CCLF) program aims to address critical hurdles in cancer control planning by: (1) convening cancer control leaders from diverse sectors; (2) raising awareness and capacity of participating country representatives to develop and implement NCCPs; (3) facilitating development of country action-plans; and (4) providing technical assistance. Two years after participating in their first CCLF, eight countries from Southeast Asia and the Pacific, represented by multiple cancer control leaders from each country, participated in an Asia-Pacific Leadership Forum Phase II (APLF2) in 2016. The APLF2 facilitated valuable experience-exchange amongst regional and international experts, and explored areas of common interest, including: improving cancer registries, strengthening training, coordinating stakeholders, maximizing resources and overcoming implementation challenges. These priorities guide on-going cancer control efforts and serve to inform the international community of trends, needs and challenges in cancer control in Southeast Asia and the Pacific.

13 March 2024 in mBio
Verified
Journal Article
Open access
TSTulika Singh
Tulika Singh
IMItzayana G. Miller
Itzayana G. Miller
SVSravani Venkatayogi
Sravani Venkatayogi
HWHelen Webster
Helen Webster
HHHolly J. Heimsath
Holly J. Heimsath
SPSallie Permar
Sallie Permar
Immunodominant and highly conserved flavivirus envelope proteins can trigger cross-reactive IgG antibodies against related flaviviruses, which shapes subsequent protection or disease severity. This study examined how prior dengue serotype 3 (DENV-3) infection affects subsequent Zika virus (ZIKV) plasmablast responses in rhesus macaques ( n = 4). We found that prior DENV-3 infection was not associated with diminished ZIKV-neutralizing antibodies or magnitude of plasmablast activation. Rather, characterization of 363 plasmablasts and their derivative 177 monoclonal antibody supernatants from acute ZIKV infection revealed that prior DENV-3 infection was associated with a differential isotype distribution toward IgG, lower somatic hypermutation, and lesser B cell receptor variable gene diversity as compared with repeat ZIKV challenge. We did not find long-lasting DENV-3 cross-reactive IgG after a ZIKV infection but did find persistent ZIKV-binding cross-reactive IgG after a DENV-3 infection, suggesting non-reciprocal cross-reactive immunity. Infection with ZIKV after DENV-3 boosted pre-existing DENV-3-neutralizing antibodies by two- to threefold, demonstrating immune imprinting. These findings suggest that the order of DENV and ZIKV infections has impact on the quality of early B cell immunity which has implications for optimal immunization strategies. IMPORTANCE: The Zika virus epidemic of 2015–2016 in the Americas revealed that this mosquito-transmitted virus could be congenitally transmitted during pregnancy and cause birth defects in newborns. Currently, there are no interventions to mitigate this disease and Zika virus is likely to re-emerge. Understanding how protective antibody responses are generated against Zika virus can help in the development of a safe and effective vaccine. One main challenge is that Zika virus co-circulates with related viruses like dengue, such that prior exposure to one can generate cross-reactive antibodies against the other which may enhance infection and disease from the second virus. In this study, we sought to understand how prior dengue virus infection impacts subsequent immunity to Zika virus by single-cell sequencing of antibody producing cells in a second Zika virus infection. Identifying specific qualities of Zika virus immunity that are modulated by prior dengue virus immunity will enable optimal immunization strategies.